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A B S T R A C T
Rett Syndrome (RTT) is an X-linked neurodevelopmental disorder associated with respiratory abnormalities and,
in up to ~40% of patients, with prolongation of the cardiac QTc interval. QTc prolongation calls for cautious use
of drugs with a propensity to inhibit hERG channels. The STARS trial has been undertaken to investigate the
efficacy of sarizotan, a 5-HT1A receptor agonist, at correcting RTT respiratory abnormalities. The present study
investigated whether sarizotan inhibits hERG potassium channels and prolongs ventricular repolarization.
Whole-cell patch-clamp measurements were made at 37 °C from hERG-expressing HEK293 cells. Docking ana-
lysis was conducted using a recent cryo-EM structure of hERG. Sarizotan was a potent inhibitor of hERG current
(IhERG; IC50 of 183 nM) and of native ventricular IKr from guinea-pig ventricular myocytes. 100 nM and 1 μM
sarizotan prolonged ventricular action potential (AP) duration (APD90) by 14.1 ± 3.3% (n=6) and
29.8 ± 3.1% (n=5) respectively and promoted AP triangulation. High affinity IhERG inhibition by sarizotan
was contingent upon channel gating and intact inactivation. Mutagenesis experiments and docking analysis
implicated F557, S624 and Y652 residues in sarizotan binding, with weaker contribution from F656. In con-
clusion, sarizotan inhibits IKr/IhERG, accessing key binding residues on channel gating. This action and con-
sequent ventricular AP prolongation occur at concentrations relevant to those proposed to treat breathing
dysrhythmia in RTT. Sarizotan should only be used in RTT patients with careful evaluation of risk factors for QTc
prolongation.
1. Introduction
Rett Syndrome (RTT) is a severe X-chromosome-linked develop-
mental disorder characterized by cognitive and motor skill deficits,
together with autistic spectrum features, seizures and microencephaly
[1–3]. The condition is strongly associated with autonomic dysfunction,
manifested in respiratory difficulties (including hyperventilation,
breath-holding and air swallowing) and abnormal heart rate control
[1,3]. Patients with RTT are almost exclusively female; males exhibit
more severe respiratory and heart rate abnormalities and most die
within a year of birth [2]. RTT is usually caused by mutations in the X-
linked transcriptional regulator gene that encodes methyl-CpG-binding
protein 2 (MECP2) [2,4–7]. MECP2 gene mutations were identified
in>95% of individuals with RTT [8]. Approximately 26% of deaths in
RTT are sudden and unexpected [9]. A proportion of RTT patients ex-
hibit prolongation of the rate-corrected QT (QTc) interval and T wave
abnormalities [10–14]., which appear to be independent of electrolyte
abnormalities [11]. In 1994 Sekul and colleagues reported lengthened
QTc intervals and T wave abnormalities in 41% of girls with RTT
compared to age-matched healthy controls [10]. The proportion of QT
interval/T wave abnormalities increased with increasing severity of
disease [10]. A subsequent study of a cohort of 34 RTT patients showed
a prolonged QTc interval in 9 patients and an upper borderline value in
10 patients; QTc prolongation was present in the absence of electrolyte
abnormalities [11]. Examination of 74 females with RTT syndrome and
10 with an atypical RTT variant with preserved speech found QTc
prolongation in 55% of girls with classic RTT compared to 20% with the
atypical variant [12].
Similar to humans, both mouse and primate models of MECP2
linked RTT manifest QTc interval prolongation [13–16]. Experiments
on 2–3month old Mecp2null/Y mice have revealed these to exhibit
longer QTc intervals than those from wild-type (WT) mice, in the
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absence of any obvious structural or contractile abnormality [13].
Whole-cell patch-clamp recordings from isolated ventricular myocytes
from Mecp2null/Y mice showed no change in peak sodium current (INa)
elicited on step depolarization to −20mV, but showed an increased
persistent, late sodium current component, INa,Late [13]. Thus, pro-
longed QTc intervals in RTT may result from enhanced ventricular
INa,Late [13].
There are currently no specific treatments for breathing abnormal-
ities in RTT. However, in mouse models of RTT, the investigational drug
sarizotan (5-HT1A agonist, D2 partial agonist) has been found to correct
irregular breathing patterns and reduce the incidence of apnoeas [17].
The STARS (Sarizotan Treatment of Apneas in Rett Syndrome) double-
blind, placebo-controlled clinical study [18] is investigating tolerability
of sarizotan for apnoea treatment in RTT patients. As RTT is associated
with QTc interval prolongation, it is important that drug treatments for
respiratory, cognitive or motor deficits in the syndrome do not ex-
acerbate this phenotype, as QTc prolongation carries a risk of Torsades
de Pointes (TdP) arrhythmia and sudden death [19,20]. Virtually all
drugs associated with QTc prolongation inhibit potassium channels
encoded by hERG (human Ether-à-go-go Related Gene; alternative no-
menclature KCNH2), which mediate the cardiac rapid delayed rectifier
K+ current, IKr [20,21]. There are currently no published studies ad-
dressing the issue as to whether or not sarizotan inhibits the hERG
channel. The present study was undertaken to address this. It demon-
strates that sarizotan produces potent inhibition of hERG K+ channel
current (IhERG) and prolongs ventricular repolarization, findings of
critical importance for the deployment of the drug in the RTT patient
population.
2. Methods
2.1. Wild-type and mutant hERG channels
Human Embryonic Kidney (HEK293) cells stably expressing wild-
type (WT) hERG were generously donated by Dr. Craig January,
University of Wisconsin [22]. A cell line stably expressing Y652A hERG
was created in the laboratory by Milnes et al. [23]. hERG mutations
were constructed using QuikChange site-directed mutagenesis (Strata-
gene, La Jolla, CA) as previously reported [24,25]. The complementary
oligonucleotide primers used for F656 V mutation construction were:
Forward 5′- GTATGCTAGCATCGTCGGCAACGTGTCG −3′ and Reverse
5’-CGACACGTTGCCGACGATGCTAGCATAC-3′. All the mutations were
confirmed by entire open reading frame sequencing (Eurofins MWG
Operon, Ebersberg, Germany).
2.2. Cell maintenance and transfection
Cells were maintained and passaged as described previously
[24,26,27]. Transient transfections were conducted when the cells
reached>80% confluence, using Lipofectamine 2000 (Life Technolo-
gies, Carlsbad, CA) according to the manufacturer's instructions. Ex-
pression plasmid encoding CD8 (in pIRES, donated by Dr. I Baró, Uni-
versity of Nantes, France) was also transfected. Successfully transfected
cells were detected using Dynabeads® (Invitrogen, Paisley, UK). Cells
were incubated at 37 °C for a minimum of 24 h prior to any electro-
physiological recording.
2.3. Guinea-pig ventricular myocyte isolation
Guinea-pig ventricular myocytes have utility in evaluating the
consequences of hERG channel blocking drugs [26,28]. Left ventricular
myocytes from guinea-pig heart were isolated by enzymatic and me-
chanical dispersion as described previously [26,29,30]. Male Dunkin
Hartley Guinea-pigs (Marshall BioResources) were killed in accordance
with UK Home Office legislation. Briefly, guinea-pigs (300-600 g) were
terminally anesthetized with pentobarbital sodium (140mg/kg, I.P.)
together with heparin (4000 U/kg). The heart was removed quickly and
was then cannulated and perfused via a Langendorff perfusion system at
37 °C. The basic perfusion solution contained (mM): 130 NaCl, 5.4 KCl,
5 HEPES, 10 Glucose, 0.4 NaH2PO4, 3 MgCl2, 20 taurine and 10 crea-
tine (pH 7.61 with NaOH). First, this basic solution with added CaCl2
(750 μM) was perfused for 2min, followed by the basic solution for
5min [29]. This was followed by low Ca2+ (150 μM) solution con-
taining collagenase (Type I, Worthington 0.3 mg/ml per 100g body
weight) and protease (Type XIV, Merck 0.01mg/ml per 100g body
weight) for 4–7min. Cells were then released from left ventricle by
mechanical dispersion. Isolated myocytes were stored in low calcium
solution (150 μM) at room temperature. For recording, an aliquot of the
cell suspension was transferred into a chamber mounted on the mi-
croscope and left to settle for several minutes, before being exposed to
normal Tyrode solution. Only cells with clear rod-shape and striated
appearance were chosen for recording.
2.4. Electrophysiological recordings
Whole-cell patch-clamp experiments were performed using an
Axopatch-1D amplifier and Digidata 1322A or 1440A (Molecular
Devices, USA). Protocols were generated, and data recorded online with
pClamp 8.0 or 10.0 (Molecular Devices, USA). The digitization rate was
10–20 kHz. Patch-pipettes (A-M Systems, USA) were pulled using a
vertical electrode puller (Narishige PP-83, Japan), and heat-polished to
a final resistance of 2–3MΩ (Narishige MF-83, Japan). Capacitance and
series resistance were routinely compensated, with series resistance
compensation of ~70%. Conventional whole-cell patch-clamp record-
ings were made to measure hERG current (IhERG) from HEK 293 cells
expressing WT or mutant hERG channels, and native delayed rectifier
potassium current (IKr) from guinea-pig ventricular myocytes. Guinea-
pig action potentials (APs) were recorded using perforated-patch with
400 μg/ml amphotericin B in pipette solution. All measurements were
performed at 37 °C.
A standard voltage-protocol (lower trace of Fig. 1A) was applied
from a holding potential of −80mV to measure IhERG. The protocol
incorporated a brief (50ms) pre-pulse from −80 to −40mV prior to
the +20mV test command, in order to quantify the instantaneous
current at −40mV. Comparison between this instantaneous current
and the peak outward IhERG tail amplitude on repolarization to −40mV
enabled the accurate measurement of IhERG tail amplitude [31,32]. The
sweep start-to-start interval was 12 s. The protocol used to investigate
voltage-dependence of inhibition of IhERG by sarizotan was like that
shown in Fig. 1A, but with test voltages between −40 and+40mV.
Action potential voltage clamp (AP clamp) experiments employed a
human epicardial ventricular AP waveform (Fig. 2A) from the ten
Tusscher et al ventricle model [33] identical to that used in prior ex-
periments from our laboratory (e.g. [31]). AP commands were applied
every 3 s and online leak subtraction was performed using a P/4 pro-
tocol [34]. An ‘envelope of tails’ protocol (lower traces in Fig. 3A) was
used to investigate the development of inhibition of IhERG by sarizotan
with time following membrane depolarization. From holding of
−80mV, cell membrane potential was depolarized to +20mV in steps
of incrementing duration from 10ms to 810ms; the amplitude of IhERG
tails on repolarization to −40mV reflected the extent of IhERG activa-
tion produced during the pulses to +20mV. The protocol used to in-
vestigate IhERG ‘availability’ is shown in Fig. 4A. From −80mV, the
membrane potential was stepped to +40mV for 500ms; this was then
followed by 2ms repolarization steps to potentials ranging from −140
to +50mV; membrane potential was then stepped back to +40mV for
100ms. The amplitude of current transients elicited by the second step
to +40mV was used to assess IhERG availability. The protocol to mea-
sure IKr was comprised of a brief step from −80 to −40mV (to in-
activate fast Na channels), followed by a 500ms step to +20mV and
repolarization to −40mV to observe IKr tails (lower trace of Fig. 2B)
[35]. The sweep start-to-start interval was 10 s. Action potentials from
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guinea-pig myocytes were elicited in current-clamp mode, by brief
(5 ms) duration suprathreshold depolarizing current pulses at a stimu-
lation frequency of 0.1 Hz.
2.5. Computational docking
Computational docking was conducted using the open pore cryo-EM
structure of hERG [PDB: 5VA1] [36], as recently described [27] using
GOLD following the methods described in [37]. Free side chain flex-
ibility was allowed during docking for selected residues within the
potential drug binding site within the hERG pore to accommodate and
optimize drug interactions. The potential binding site was centred
above the β−carbon of the chain-A Tyr-652 side chain and a radius of
10 or 12 Å was selected to allow the sarizotan molecule to sample
configurational space within the chain A hydrophobic pocket and also
the surrounding parts of the hERG pore. Due to the large number of
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Fig. 1. (A) Upper traces show IhERG in control solution and in the presence of 100 nM and 10 μM sarizotan; voltage protocol shown as lower trace. Inset shows
recordings from a separate experiment, showing partial reversibility of 1 μM sarizotan. Cross-over of washout and control IhERG tails is consistent with ‘foot-in-the
door’ inhibition. (B) Concentration-response relation for IhERG inhibition. Mean fractional block of IhERG is shown plotted against corresponding drug concentration.
Replicate numbers at each concentration shown in brackets. IC50 and nH values given in “Results” text. (C) Representative traces of IhERG in control (black) and
100 nM sarizotan (grey) at selected potentials during protocol like that in A, but with test potentials between −40 and+40mV. (D) Mean fractional block of IhERG
tails by 100 nM sarizotan plotted against test voltage (n=7). Activation relations for control and sarizotan are shown superimposed (V0.5 and k values in the main
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Fig. 2. (A) Representative traces of IhERG in control and 100 nM elicited by ventricular AP clamp (AP shown superimposed). (B) Representative traces of guinea-pig
ventricular deactivating IKr tails (elicited on repolarization to −40mV following 500ms command to +20mV) in control, 1 μM sarizotan and 10 μM E-4031.
Sarizotan was applied in these experiments for 3–5min and 1 μM E-4031 for 1 min. (C) Ventricular APs (elicited at 0.1 Hz) in control solution, after 100 nM and 1 μM
sarizotan and following washout. Mean AP duration at 25% and 90% repolarization (APD25 and APD90) values are given in the main text.
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rotamers sampled during docking 300,000 generations of the genetic
algorithm was used; the ChemPLP scoring function was used to select
low energy score docking poses from a set of 100 docking runs for each
of the sarizotan enantiomers.
2.6. Data analysis
Data are presented as mean ± SEM. Statistical analysis and fits to
data sets were performed using Microsoft Excel (Microsoft Corporation,
USA), Origin 7.0 (OriginLab, USA), Prism 7.04 (Graphpad Software
Inc., USA) and Clampfit of pClamp 10.7 (Molecular Devices, USA). Data
distribution was tested using the Kolmogorov–Smirnov normality test.
Comparisons were made using paired t-test, unpaired t-test; Wilcoxon
signed rank test, or one-way ANOVA followed by a Tukey post-test as
appropriate; P < .05 was taken as significant. The following standard
eqs. [24,26] were used to fit particular data-sets:
Fractional block of IhERG was determined using an equation of the
form:
= –( / )Fraction block 1 I residual I controlhERG hERG (1)
where IhERG control represents current amplitude prior to drug appli-
cation and IhERG residual represents the unblocked current remaining
following drug exposure.
Concentration-response data were fitted with a Hill equation of the
form:
= +/( ^(( ) ))hFractional block 1 1 10 LogIC X50 (2)
where Fractional block refers to the degree of inhibition of IhERG by a
given concentration of sarizotan (X, the logarithm of concentration);
IC50 is [sarizotan] producing half-maximal inhibition of IhERG, and h is
the Hill coefficient for the fit.
Voltage-dependent activation parameters were derived from cur-
rent-voltage (I-V) relations for IhERG tail currents, fitted with a
Boltzmann equation of the form:
= +/( (( )/ )). kI I 1 exp V Vmax 0 5 m (3)
where I is tail current magnitude at −40mV following a voltage test
potential (Vm); Imax is the maximal tail current during the voltage
protocol; V0.5 is the voltage at which IhERG is half maximally activated,
and k is the slope factor for the relation.
Continuous plots of IhERG activation were produced by inserting the
values for V0.5 and k obtained from Eq. (3) into the equation:= +/( (( )/ )). kActivation variable 1 1 exp V V0 5 m (4)
where the terms have similar meanings to those described above for Eq.
(3).
IhERG blocking time-course from application of the envelope of tails
protocol was fitted with a single-exponential equation:
= + ( ) ( ( / ))Fractional block Y Plateau Y 1 exp x0 0 (5)
where Fractional block refers to the degree of inhibition of IhERG at a
pulse duration ‘x’; the fractional block starts at Y0, then goes to Plateau;
and τ is the time constant of development of IhERG inhibition.
Voltage dependence of IhERG availability (inactivation) was de-
termined by fitting normalized current transients with the equation:
= +( / ) – /( (( )/ )). kI I 1 1 1 exp V Vmax 0 5 m (6)
where the normalized current (I/Imax) is a ratio of a current (I) at a
membrane potential/voltage (Vm) and the maximal current (Imax)
during the voltage protocol (−140 to +50mV); V0.5 is the potential at
which IhERG was half maximally inactivated, and k is the slope factor for
the relation.
3. Results
3.1. Potency and voltage dependence of sarizotan inhibition of IhERG
Sensitivity of IhERG to sarizotan was evaluated using a previously
described voltage protocol (lower trace in Fig. 1A) [23,24]. In the ex-
ample shown the IhERG tail was inhibited by 37% at 100 nM and by 96%
at 10 μM sarizotan. The inset shows partial reversibility of the response
to sarizotan (1 μM). A total of 5 concentrations were tested and a mean
concentration-response plot was constructed (Fig. 1B), yielding an IC50
of 183 ± 51 nM, with a Hill co-efficient (nH) of 0.58 ± 0.10. Sarizotan
action on IhERG tails following different test potentials was assessed
using a similar protocol, but with test voltages between −40
and+ 40mV. Representative current traces are shown in Fig. 1C. IhERG
tail block by 100 nM sarizotan was evaluated following the different
command voltages and plotted as shown in Fig. 1D. Tail currents in
control and drug following the different test potentials were fitted with
a Boltzmann function and mean derived V0.5 and k values then used to
construct activation plots, superimposed in Fig. 1D. Voltage dependent
activation was leftward shifted in sarizotan compared to control (V0.5 in
sarizotan of −29.9 ± 2.3mV and in control of −24.2 ± 1.9mV,
P < .05; k in sarizotan of 6.1 ± 0.8 and in control 5.7 ± 0.3,
P > .84, n=7; Wilcoxon matched-pairs signed rank test for both). The
progressive changes in extent of IhERG block by sarizotan coincided with
the steep phase of IhERG activation, consistent with activation-depen-
dent inhibition [26]. Over potentials (between +10 and+40mV) at
the top of the voltage-dependent activation relation there was no sig-
nificant change in the extent of fractional inhibition, suggesting that
voltage-dependence of inhibition independent of channel gating did not
occur.
3.2. Effects of sarizotan on ventricular action potentials and IKr
Fig. 2A shows effects of 100 nM of sarizotan on IhERG elicited by a
ventricular AP waveform. Peak repolarizing current occurred at
−38.6 ± 1.6mV in control and− 35.2 ± 2.7mV in sarizotan
(P > .05, paired t-test; n=7). It was reduced by 33.0 ± 3.2% in
sarizotan (P > .05, cf standard protocol (35.4 ± 2.6%; n=9) un-
paired t-test). We evaluated block of native ventricular IKr using a
protocol comprised of a brief step from −80 to −40mV (to inactivate
fast Na channels), followed by a 500ms step to +20mV and repolar-
ization to −40mV to observe IKr tails. 1 μM sarizotan suppressed de-
activating tail current amplitude by 66.2 ± 1.9% (n= 7). As shown in
Fig. 2B, with subsequent application of a high concentration of E-4031
after sarizotan there was no residual tail current, confirming that under
these conditions deactivating outward current tails were carried by IKr.
We also monitored the peak inward L-type Ca2+ current (ICa,L) at the
start of the +20mV step of this protocol and observed only a small
(18.4 ± 3%; n=7) reduction in that current with 1 μM sarizotan (not
shown). Fig. 2C shows the effect of 100 nM and 1 μM sarizotan on
ventricular AP duration (APD). 100 nM sarizotan prolonged action
potential duration at 25% repolarization (APD25) by 3.1 ± 1.8% and
action potential duration at 90% repolarization (APD90) by
14.1 ± 3.3% (n=6), whilst 1 μM sarizotan prolonged APD25 by
3.8 ± 1.2% and APD90 by 29.8 ± 3.1% (n=5). AP triangulation [38]
was measured as the APD25 to APD90 difference. This was
100.7 ± 7.6ms in control, 126.4 ± 10.7ms in 100 nM sarizotan and
173.9 ± 9.9ms in 1 μM sarizotan (P < .01 vs control for both; one-
way ANOVA with Tukey post-test). Significant triangulation was also
observed when measured as APD30-APD90 difference (see Table 1).
Thus, sarizotan both prolonged ventricular APD and increased AP tri-
angulation.
3.3. Time dependence and effect of sarizotan on IhERG inactivation
Time-dependence of IhERG block was explored using two
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complementary approaches. The first of these utilized a protocol com-
prised of a long (10 s) duration depolarization from −80 to 0mV [39],
which was applied first in control solution and then in 100 nM sar-
izotan, after resting the cell at −80mV in sarizotan for ~3min (re-
presentative traces are shown in supplemental Fig. S1A). As shown in
Fig. S1B, a substantial component of the block observed at 10 s at 0mV
occurred by 100–200ms into the depolarizing command, indicating
that block was evident quickly on membrane depolarization. However,
as highlighted previously in this journal, this protocol is less suited to
examination of block over comparatively shorter than longer periods
following membrane depolarization [40]. Consequently, we also em-
ployed an envelope of tails protocol (with depolarizing commands to
+20mV of differing duration, shown as lower traces in Fig. 3A, with
representative currents shown as the upper traces) [35,40,41]. This was
applied in control, the cell then rested for ~3min during exposure to
100 nM sarizotan, and then reapplied. Fractional inhibition of the tail
currents following the different duration voltage commands was then
determined and plotted against test pulse duration as shown in Fig. 3B
(n=5). There was little or no block with very short voltage commands,
and block increased progressively over ~200ms. A single exponential
fit to these data gave a blocking τ of 34.4ms. These results demonstrate
that sarizotan's action was contingent upon channel gating with little or
no block of resting channels.
Fig. 4A shows the protocol used to evaluate voltage dependent
availability of IhERG, from which inactivation V0.5 and k values were
obtained [42,43]. Fig. 4B and C respectively show representative traces,
focusing on the portion of the protocol including brief repolarizing
steps (to produce differing extents of IhERG availability) and the sub-
sequent outward IhERG transients during the final step of the protocol.
Plots of IhERG availability (Fig. 4D) were constructed as described pre-
viously [42] and Boltzmann fits used to obtain inactivation V0.5 and k
values (V0.5 in sarizotan of −45.3 ± 5.0mV and in control of
−57.9 ± 4.5mV; P > .05, n=7 paired t-test; k in sarizotan of
23.1 ± 1.1 and in control of 26.3 ± 1.9, P > .05, n=7; paired t-
test). Time-course of inactivation was evaluated for current following a
brief conditioning pulse to −120mV and was not significantly altered
by sarizotan (τ values of 1.74 ± 0.43 and 1.93 ± 0.22ms in control
and sarizotan respectively; P > .05; paired t-test; data not shown).
3.4. Molecular basis of sarizotan action
The effects of targeted hERG mutations on inhibition of IhERG by
1 μM and 10 μM sarizotan action were established. The N588K mutation
to the S5-Pore linker region markedly reduces IhERG inactivation and
attenuates blockade of a range of agents that rely on intact inactivation
to bind to the channel [32,44]. IhERG inhibition by both 1 μM and 10 μM
sarizotan was significantly attenuated by this mutation, indicating that
an intact inactivation process is needed for high affinity sarizotan
binding. Representative traces for the S624A mutation (located in the
pore helix/base of selectivity filter) and Y652A mutation (located in the
S6 helix) are also shown in Fig. 5A, with attenuation of block by 1 μM
sarizotan. Fig. 5B summarises effects of these mutations plus S6 F656 V
and S5 F557 L mutations, both of which also attenuated drug action.
Supplemental Table S1 provides estimates of the changes in binding
energy for sarizotan introduced by the mutations studied.
Fig. 5 Ci and 5Cii show results of in silico docking of sarizotan within
the pore of the recently determined cryo-EM hERG channel structure
[36]. Sarizotan could bind within the pore below the selectivity filter,
with a hydrophobic aromatic part of the drug projecting into one of the
hydrophobic pockets identified in the EM structure that are found at the
interface between the pore helix (PH) and S5 and S6 helices (Fig. 5 Ci).
In this configuration sarizotan made π-π stacking interactions with
F557 and Y652 aromatic side chains, and the polar amino and pyridine
nitrogens lay below the C-terminal end of the pore helix with possible
direct or water-mediated interactions with the T623 and S624 hydroxyl
side chains (Fig. 5Cii); interactions with F656 in this configuration were
minimal. This docking pose is consistent with the mutagenesis data
summarized in Fig. 5B. The specific binding interactions between sar-
izotan and S624, Y652 and F557 are further highlighted in the stereo
view in supplemental Fig. S2.
4. Discussion
4.1. Sarizotan interaction with the hERG channel
This study demonstrates that sarizotan inhibits both IhERG and na-
tive IKr at sub-micromolar concentrations (IC50 for IhERG block of
183 nM), prolongs ventricular APD90 and increases ventricular AP tri-
angulation, which is a marker of proarrhythmic risk [38]. The observed
potency of sarizotan inhibition of IhERG can usefully be considered in
the context of IC50 values obtained in our laboratory under similar
experimental conditions for established IhERG inhibitors. Thus, using the
standard protocol shown in Fig. 1A, we have previously obtained IhERG
IC50 values for the canonical hERG/IKr blockers E-4031 and dofetilide of
16 nM and 9.8 nM respectively and for the Class Ia antiarrhythmic
quinidine of 620 nM [32,45]. Both dofetilide and quinidine are well
established to be linked to QTc interval prolongation [19] and it is
notable that sarizotan is a more potent inhibitor of IhERG than is qui-
nidine under similar experimental conditions.
The WT IhERG data in this study show that sarizotan relies on hERG
channel gating in order to access its binding site, whilst the N588K
mutant data demonstrate that an intact inactivation process is neces-
sary for high affinity binding [32;44]. High affinity hERG channel in-
hibition most commonly involves drug interaction with S6 aromatic
residues, with further supportive interactions with other residues on the
S6 helices and located close to the selectivity filter/base of the pore
helix [21;46]. Our mutagenesis and docking results indicate that sar-
izotan interacts with residues of the canonical drug binding site, though
it is notable that mutation at Y652 led to a greater attenuation of in-
hibition than did mutation of F656. Recent studies have shown a role
for the F557 S5 aromatic residue in IhERG block [27;47] and, here,
mutation of F557 markedly reduced IhERG block by sarizotan. F557 lies
partly within hydrophobic pockets recently identified in the cryo-EM
structure of hERG [36]. Docking to this structure shows low-energy
binding could occur in a configuration that places sarizotan near F557,
S624 at the base of the selectivity filter and Y652. The original study
that identified F557 as a potential binding determinant for hERG in-
hibitors did not directly compare effects of mutations at F557 and F656
experimentally [47]. In our prior study of a minimally structured high
affinity hERG inhibitor, Cavalli-2, mutation at F656 had greater effects
on blocking potency than mutation at either F557 or Y652 [27]. An
independent study of a novel EGFR inhibitor FHND004 also found
mutation at F656 to attenuate inhibition more than at F557 [48]. Sar-
izotan is notable in this regard as it is an IhERG inhibitor for which
mutation of F557 produces a greater attenuation of inhibition than
mutation at the canonical F656 binding residue. Interestingly, a very
Table 1
Effects of sarizotan exposure on ventricular AP repolarization parameters.
Control (n=6) Sarizotan 100 nM (n=6)
APD25 (ms) 118.4 ± 17.7 121.4 ± 17.8
APD30 (ms) 137.9 ± 20.1 142.9 ± 19.4
APD50 (ms) 189.1 ± 21.9 204.7 ± 23.9 ⁎⁎
APD60 (ms) 200.4 ± 21.6 224.3 ± 21.3 ⁎⁎
APD90 (ms) 219.0 ± 21.7 247.8 ± 21.3 ⁎⁎
APD90-APD25 (ms) 100.6 ± 9.0 126.4 ± 10.7 ⁎⁎
APD90-APD30 (ms) 81.1 ± 7.4 105.0 ± 9.5 ⁎⁎
APD refers to action potential duration and subscripted numbers refer to point
after start of repolarization at which duration was measured (values are given
for 25%, 30%, 50%, 60%, 90% of complete repolarization).
⁎⁎ denotes statistical significance of P < .01 versus control; paired t-test.
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recent independent study of the HCN channel inhibitor ivabradine has
reported IhERG inhibition by that drug to be attenuated more by the
F557L than F656C mutation [49].
4.2. Implications of the study
The STARS trial involves administration of 2 or 10mg sarizotan
bidaily (over 24weeks) to RTT patients aged ≥4 years, with a body
weight of ≥10 kg, with a primary outcome measure of reduction of
respiratory abnormalities [18]. Redfern et al proposed a safety margin
of 30 (hERG IC50/ plasma Cmax) for drugs undergoing clinical evalua-
tion [50], which would correspond to a sarizotan plasma level of
6–7 nM (for the IhERG IC50 in this study). Oral administration of 2 and
10mg of sarizotan to adult men produced peak total plasma con-
centrations of ~170 and 488 ng/ml (~ 442 nM and 1.27 μM, respec-
tively [51]). Therefore, it is expected that peak total plasma levels of
sarizotan in young RTT patients given 2 or 10mg doses may fall within
a comparable range. Although unbound levels may be substantially
lower than total plasma drug levels, it is notable that sarizotan is li-
pophilic (logP value of 4.1; PubChem CID 6918388) and so could
concentrate in lipid membranes. Feasibly, therefore, sarizotan admin-
istration could result in a safety margin of< 30. Thus, it is reasonable
to conclude that hERG/IKr block is a potential risk of sarizotan ad-
ministration to RTT patients. This would pose a particular safety
concern in the subset of RTT patients with overt QTc prolongation
[10–14]. Administration of sarizotan to primates is associated with
production of metabolites (EMD 148107, EMD 329989, EMD 50929) at
concentrations 5–10 fold lower than that of the parent compound [52].
The propensity of these metabolites to inhibit hERG/IKr and delay re-
polarization remains to be established. Exclusion criteria for the STARS
trial include a Fridericia corrected QTc interval of> 450ms. However,
in principle, individuals with a borderline QTc but impoverished re-
polarization reserve prior to drug administration could also be at sig-
nificant risk. Moreover, as female sex is itself a risk factor for drug-
induced long QT syndrome [53] long-term administration of sarizotan
(post-puberty) in RTT patients would need to be undertaken with care.
At present, there is no alternative selective treatment for the respiratory
disturbances in RTT, thus it would be premature to conclude that sar-
izotan is unsuitable due to its hERG-activity, particularly given the risk
posed by apnoeas themselves. It is noteworthy that severe breathing
dysrhythmia is independently associated with QTc prolongation in RTT
(OR=2, P= .001) [54]. Studies in neurotypical individuals suffering
from sleep apnoeas suggest a causal link [55–57] between frequent
apnoeas and QTc prolongation, but this is yet to be determined in RTT.
Recent analysis suggests that extent of QTc interval prolongation in RTT
may vary between MECP2 mutations, with R255* mutations and large
deletions being most strongly linked to QTc prolongation [58]. If this is
borne out by further investigations with larger sample sizes, mutation
A
B
Ci
Cii
Fig. 5. (A) Representative traces showing effects of sarizotan on IhERG tail current for WT, N588K, S624A and Y652A hERG channels (shown as upper sets of traces)
with expanded portion of voltage protocol shown as lower traces. (B) Bar charts showing mean fractional block of IhERG tails by 1 μM and 10 μM sarizotan for WT,
N588K, S624A, F557 L, Y652A and F656A hERG channels. Replicate numbers shown in brackets. * and ** are significance at P < .05 and P < .01 respectively (one-
way ANOVA with Tukey post-test). (Ci) Low energy score configuration for R sarizotan (yellow space filling representation) docked into the cryo-EM structure of
hERG [36]. Subunit A of the hERG pore is colored grey and the side chains shown are identified in Cii. The location of N588 in chain A is also shown. The selectivity
filter is occupied by K+ ions in the 1 and 3 positions (purple spheres) and waters in the 2 and 4 positions. The S enantiomer of sarizotan (not shown) was similarly
able to bind with a hydrophobic aromatic part of the drug projecting into a hydrophobic pocket. PH: pore helix. (Cii) Close up of the bound configuration for R
sarizotan as in panel Ci showing side chains in the binding “pocket” [36] of chain A (grey sticks) and other side chains important for binding to hERG blockers and
mentioned in the text. (For interpretation of the references to colour in this figure legend, the reader is referred to the online version of this article.)
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type as well as severity of respiratory arrhythmia could aid patient
selection for sarizotan treatment. Additionally, evaluation of the value
of other compounds with 5-HT1A agonist activity as potential alter-
native RTT treatments [59] could usefully consider their hERG-blocking
propensity (or lack thereof) alongside efficacy against respiratory dys-
rhythmia.
5. Perspectives
The results of this study demonstrate that sarizotan inhibits IhERG/
IKr and delays ventricular repolarization at concentrations relevant to
those being considered for the treatment of RTT. Given the paucity of
alternative RTT treatments, if the drug is found to be beneficial for
respiratory arrhythmias in RTT patients, the findings of this study in-
dicate that treatment should commence under clinical supervision with
close monitoring of ECG and electrolyte levels, with further caution to:
(i) use the lowest effective dose; (ii) avoid use in patients with existing
LQTS or in combination with other QTc prolonging medications; and
(iii) consider other risk factors for acquired LQTS [53].
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